Mechelen, Belgium, 4 April 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the establishment of its US subsidiary, Biocartis US Inc., and the appointment of Vishal Sikri as its US General Manager. Both are important next steps in the execution of Biocartis' US strategy following the announced commercialization agreement with Thermo Fisher Scientific Inc. in November 2016.
Biocartis is pleased to announce the appointment of Vishal Sikri as the General Manager for its US operations. Vishal is a highly experienced executive with a proven global commercial and operational track-record in molecular diagnostics. Before joining Biocartis, he was Managing Director and VP Commercial Operations responsible for all global commercial operations of Sysmex Inostics, the molecular diagnostics' division of Sysmex Corporation (TYO: 6869). Prior to that, he held various roles within Sysmex America Inc. and Sysmex Corporation, including amongst others the position of Director New Business Development. Before joining Sysmex in January 2007, Vishal held different Senior Product Management roles within Abbott Laboratories. Vishal holds a degree in Pharmaceutical Sciences (University of Wisconsin) and a Master's in Business Administration (Loyola University of Chicago).
Vishal Sikri, General Manager of Biocartis US Inc., commented: "I am very pleased to be leading the team that will build the commercial activities of Biocartis in the US, an important new market for the Company. I truly believe that with Idylla(TM), we will make a difference in the US market where there is a pressing need for easy, rapid and highly accurate oncology diagnostic solutions."
Hilde Windels, Chief Executive Officer of Biocartis, added: "Vishal has been championing commercial growth strategies in molecular diagnostics in oncology for most of his career. With a broad background varying from clinical trial management to sales & marketing, medical affairs, business development and M&A, and a particular expertise in liquid biopsy testing and companion diagnostics, we are confident that Vishal will successfully establish Biocartis in one of the largest molecular diagnostics markets in the world."
Biocartis expects to start commercial roll-out in the US of its rapid and fully automated Idylla(TM) platform and its accompanying assays, with a first focus on oncology research products, in H2 2017. The Company will open its US office in the New Jersey area.
Manager Corporate Communications & Investor Relations
tel +32 15 631 729
mobile +32 471 53 60 64
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers eight oncology tests and two infectious disease tests. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.